U.S. stocks jolted higher on Tuesday, with both the Dow and the Nasdaq climbing to records as the market’s recent advance gained momentum.
The Dow Jones Industrial Average DJIA, +0.22% rose 72 points, or 0.4%, to 20,125, and it hit an intraday record of 20,155.3 earlier in the session. The Nasdaq Composite Index COMP, +0.29% rose 19 points to 5,683, a rise of 0.4%. The index hit an intraday all-time high of 5,685.27 in early trading.
While the S&P 500 index SPX, +0.08% remains a few points from its own record, hit earlier this year, it rose 5 points to 2,298, a rise of 0.3%.
Health insurer Centene was up 2.15 percent at $65 following better-than-expected quarterly revenue and profit.
Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), with shares lower -3.08% is now trading at $1.26. The Stock is active as 499,844.00 shares changed hands versus its average volume of 507,354.00 shares. For investors focus on the performance of the stocks so the ATNM showed weekly ahead performance of 18.87% which was maintained for the month at 31.26%.
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, declared recently that a Phase 1 clinical trial studying Actimab-M in multiple myeloma has been initiated. Actimab-M is comprised of the CD-33 targeting monoclonal antibody HuM-195 coupled to the alpha-particle emitter actinium 225. CD33 is an antigen found on hematopoietic cells in certain blood cancers. It is commonly associated with myeloid malignancies counting AML, but recent research has shown that CD33 can also be found on malignant cells of about 25%-35% of all multiple myeloma patients. Furthermore, the expression of this marker increases in relapsed and refractory myeloma. In addition, it predicts for a very aggressive course of disease. This makes CD33 a potential target for the treatment of this usually fatal disease. Although treatable, multiple myeloma is presently not considered curable and almost all patients eventually relapse or become refractory to available treatments as their condition progresses. In this new trial, Actimab-M will be used in patients who have progressing disease after 3 prior multiple myeloma treatment regimens or are refractory to QUAD (Caflizomib, Lenalidomide, Pomalidomide, Dexamethason).
“I am very anxious to lead in the development of this novel and promising approach,” said Dr. M. Yair Levy of Texas Oncology – Baylor Charles A. Sammons Cancer Center. “Relapsed and refractory multiple myeloma is an area of high unmet medical need that we hope to address with Actimab-M. Myeloma is a very radiosensitive cancer, and does not present with the neutropenia and thrombocytopenia of AML. I would expect tolerability of this treatment to be better in this disease. Based on my previous experience with Actimab-A in AML and my research in the area of multiple myeloma, I believe that this targeted treatment could prove efficacious and be a part of our growing armamentarium against this disease.”
Lannett Company, Inc. (NYSE:LCI), with shares surged 1.73% is now trading at $20.60. The Stock is active as 469,368.00 shares changed hands versus its average volume of 1.22M shares. The stock is going forward its 52 week low with 22.69% and lagging behind from its 52 week high price with -48.61 %. LCI last month stock price volatility remained 5.82%.
Lannett Company, Inc. (LCI) recently declared that it has accomplished the extraction of the core software supporting the operations of Kremers Urban Pharmaceuticals, Inc. (KU) from UCB Pharma.
“Having performed a successful targeted extraction of KU’s SAP data and configuration is a noteworthymilestone and paves the way for KU’s operational independence,” said Robert Ehlinger, chief information officer of Lannett.
“Data extraction of an ERP system is complicated and I am happy to report that our business did not skip a beat during the process,” said Arthur Bedrosian, chief executive officer of Lannett. “Our IT team thoroughly planned and executed every step along the way to ensure a seamless transition. I want to acknowledge the excellence of our IT department with regard to this extraction, in addition to their efforts to implement SAP in our Silarx and Cody Laboratories auxiliaries.”